IL27 and graft versus host disease: When IL-27 pre-treated iTregs were used, the mean survival kinetics was not different from the first two groups (p = 0.1693 vs. GvHD group; p = 0.3749 vs. control iTregs); however, ~30% mice survived until day 100 post-BMT without any noticeable GvHD symptoms (Figure 6E).